Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by UroGen Pharma Ltd. < Previous 1 2 3 Next > UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants June 17, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC June 13, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024 June 06, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference June 05, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma Appoints David Lin as New Chief Commercial Officer June 03, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit May 22, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights May 13, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma to Participate at Upcoming Investor Conferences May 07, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy May 05, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024 May 04, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial May 04, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024 May 03, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers April 17, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer April 15, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals April 03, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102 March 14, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 08, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024 March 04, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference February 26, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma to Participate at Upcoming Investor Conferences February 01, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102 January 24, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers January 17, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma to Participate in the B. Riley Healthcare Conference January 11, 2024 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 08, 2023 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma Reports Third Quarter 2023 Financial Results November 14, 2023 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology November 13, 2023 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023 November 07, 2023 From UroGen Pharma Ltd. Via Business Wire Tickers URGN Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024 October 03, 2023 From UroGen Pharma Ltd. Via Business Wire Tickers URGN UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 08, 2023 From UroGen Pharma Ltd. Via Business Wire Tickers URGN < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.